SCHEMBL316671

SCHEMBL316671

N#Cc1cc(-c2ccccc2)cc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 4/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
ADRB2 P07550 1/20 0.47
KDM4E B2RXH2 4/20 0.45
GAA P10253 1/20 0.45
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
KMT2A Q03164 4/20 0.44
HPGD P15428 3/20 0.44
MEN1 O00255 2/20 0.44
GLA P06280 1/20 0.44
POLB P06746 1/20 0.44
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8547523 0.86 KDM4E (0.51) SMN1; SMN2LMNAL3MBTL1MAPTTDP1
SCHEMBL26638906 0.82 KDM4E (0.42) KDM4EALDH1A1KMT2AHPGDMEN1
SCHEMBL4000527 0.80 KDM4E (0.52) SMN1; SMN2LMNAL3MBTL1MAPTTDP1
SCHEMBL27901846 0.79 KDM4E (0.58) SMN1; SMN2LMNAL3MBTL1MAPTTDP1
SCHEMBL27919545 0.78 SMN1; SMN2 (0.62) SMN1; SMN2LMNAL3MBTL1MAPTTDP1
SCHEMBL10253381 0.78 KDM4E (0.49) SMN1; SMN2LMNAL3MBTL1MAPTKDM4E
SCHEMBL20396108 0.78 CYP1A2 (0.52) SMN1; SMN2LMNAL3MBTL1MAPTTDP1
SCHEMBL19356978 0.76 AKR1C2 (0.43) KDM4EADORA1
SCHEMBL30938605 0.74 SMN1; SMN2 (0.51) SMN1; SMN2LMNAL3MBTL1MAPTTDP1
SCHEMBL19697639 0.74 SMN1; SMN2 (0.51) SMN1; SMN2LMNAL3MBTL1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081903-B1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-05-07 EP disclosed
EP-2081903-B1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-05-07 EP disclosed
US-8093250-B2 2-aminocarbonyl-pyridine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-01-10 US disclosed
US-8058263-B2 Substituted 2-phenyl-pyridine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2011-11-15 US disclosed
US-20110046089-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2011-02-24 US disclosed
EP-2279191-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2011-02-02 EP disclosed
US-20100035895-A1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-02-11 US disclosed
WO-2009125366-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-10-15 WO disclosed
WO-2009125366-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-10-15 WO disclosed
EP-2081903-A2 2-AMINOCARBONYL-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-29 EP disclosed
WO-2008044217-A2 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-17 WO disclosed
WO-2008044217-A2 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035895-A1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES P2RY12, P2RY2, P2RY1 SMN1; SMN2 3232/4885LMNA 2766/4885L3MBTL1 4786/4885
US-20110046089-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES P2RY12, P2RY13, P2RY11 SMN1; SMN2 3114/4885LMNA 2647/4885L3MBTL1 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.